Biomarkers in Gastrointestinal Cancer: Applying the Latest Data in Community Practice

Interact with an expert during a 1-hour, CME/CNE/CPE-certified live meeting examining recent advances and current best practices in biomarker-driven treatment for gastrointestinal cancers. Register today!


  • Histology-Agnostic Biomarkers in GI Malignancies
  • Biomarker-Driven Treatment of Advanced Colorectal Cancer
  • Biomarker-Driven Treatment of Gastric, Esophageal, Gastroesophageal Junction, Pancreatic, and Biliary Tract Cancers
  • Live Audience Question and Answer Session


Date / Time
Event Details


James M. Cleary, MD, PhD

Assistant Professor of Medicine
Harvard Medical School
Associate Director of Clinical Research
Gastrointestinal Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Pashtoon M. Kasi, MD, MS

Director, Colon Cancer Research and Precision
Medical Director for Liquid Biopsy
Weill Cornell Medicine/Englander Institute of Precision Medicine
Assistant Professor (Interim)
Weill Cornell Medicine
New York, New York

Christopher H. Lieu, MD

Associate Professor
Associate Director for Clinical Research

Division of Medical Oncology
University of Colorado Cancer Center
Division of Medical Oncology
University of Colorado Hospital
Aurora, Colorado

Goal Statement

The goal of this program is to improve the knowledge, confidence, and competence of learners in biomarker testing to guide selection of individualized treatments for patients with gastrointestinal malignancies.

Target Audience

This program is intended for oncologists, surgeons, pathologists, nurses, pharmacists, and other healthcare professionals who treat and manage patients with gastrointestinal cancers.

Learning Objectives

  • Apply the available data and expert recommendations to determine which biomarkers should be assessed in your patients with GI malignancies
  • Plan therapeutic strategies for patients with GI malignancies based on predictive biomarker assessment
  • Counsel patients about how the molecular profile will guide therapy decisions and potential need for additional biopsy
  • Appraise ongoing clinical trials for novel biomarker-driven treatment strategies in GI malignancies for patient counsel and potential enrollment


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. 

In-person UAN:  JA4008176-0000-22-011-L01-P

Virtual/Simulcast: JA4008176-0000-22-012-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.